IBDEI0UP ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15142,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,15142,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,15143,0)
 ;;=288.09^^89^902^8
 ;;^UTILITY(U,$J,358.3,15143,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15143,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,15143,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,15143,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,15144,0)
 ;;=V10.21^^89^902^61
 ;;^UTILITY(U,$J,358.3,15144,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15144,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,15144,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,15144,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,15145,0)
 ;;=284.2^^89^902^106
 ;;^UTILITY(U,$J,358.3,15145,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15145,1,4,0)
 ;;=4^284.2
 ;;^UTILITY(U,$J,358.3,15145,1,5,0)
 ;;=5^Myelophthisic Anemia
 ;;^UTILITY(U,$J,358.3,15145,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,15146,0)
 ;;=202.40^^89^902^76
 ;;^UTILITY(U,$J,358.3,15146,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15146,1,4,0)
 ;;=4^202.40
 ;;^UTILITY(U,$J,358.3,15146,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspecified site
 ;;^UTILITY(U,$J,358.3,15146,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,15147,0)
 ;;=287.49^^89^902^118
 ;;^UTILITY(U,$J,358.3,15147,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15147,1,4,0)
 ;;=4^287.49
 ;;^UTILITY(U,$J,358.3,15147,1,5,0)
 ;;=5^Thrombocytopenia,Drug Induced
 ;;^UTILITY(U,$J,358.3,15147,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,15148,0)
 ;;=180.9^^89^902^29
 ;;^UTILITY(U,$J,358.3,15148,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15148,1,4,0)
 ;;=4^180.9
 ;;^UTILITY(U,$J,358.3,15148,1,5,0)
 ;;=5^Ca Cervix
 ;;^UTILITY(U,$J,358.3,15148,2)
 ;;=^267214
 ;;^UTILITY(U,$J,358.3,15149,0)
 ;;=203.02^^89^902^104
 ;;^UTILITY(U,$J,358.3,15149,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15149,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,15149,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,15149,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,15150,0)
 ;;=204.02^^89^902^2
 ;;^UTILITY(U,$J,358.3,15150,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15150,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,15150,1,5,0)
 ;;=5^ALL,In Relapse
 ;;^UTILITY(U,$J,358.3,15150,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,15151,0)
 ;;=204.12^^89^902^17
 ;;^UTILITY(U,$J,358.3,15151,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15151,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,15151,1,5,0)
 ;;=5^CLL,In Relapse
 ;;^UTILITY(U,$J,358.3,15151,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,15152,0)
 ;;=204.20^^89^902^114
 ;;^UTILITY(U,$J,358.3,15152,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15152,1,4,0)
 ;;=4^204.20
 ;;^UTILITY(U,$J,358.3,15152,1,5,0)
 ;;=5^Subacute LL w/o Remission
 ;;^UTILITY(U,$J,358.3,15152,2)
 ;;=^336852
 ;;^UTILITY(U,$J,358.3,15153,0)
 ;;=204.21^^89^902^116
 ;;^UTILITY(U,$J,358.3,15153,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15153,1,4,0)
 ;;=4^204.21
 ;;^UTILITY(U,$J,358.3,15153,1,5,0)
 ;;=5^Subacute LL,In Remission
 ;;^UTILITY(U,$J,358.3,15153,2)
 ;;=^267526
 ;;^UTILITY(U,$J,358.3,15154,0)
 ;;=204.22^^89^902^115
 ;;^UTILITY(U,$J,358.3,15154,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15154,1,4,0)
 ;;=4^204.22
 ;;^UTILITY(U,$J,358.3,15154,1,5,0)
 ;;=5^Subacute LL,In Relapse
 ;;^UTILITY(U,$J,358.3,15154,2)
 ;;=^336467
 ;;^UTILITY(U,$J,358.3,15155,0)
 ;;=205.02^^89^902^5
 ;;^UTILITY(U,$J,358.3,15155,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15155,1,4,0)
 ;;=4^205.02
 ;;^UTILITY(U,$J,358.3,15155,1,5,0)
 ;;=5^AML,In Relapse
 ;;^UTILITY(U,$J,358.3,15155,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,15156,0)
 ;;=205.12^^89^902^20
